INSM Key Stats
- Insmed Reports 2013 Fourth Quarter and Full Year Financial Results noodls 03/06 08:47 ET
- Insmed, Inc. (INSM) Posts Q4 Loss of 41c/Share Street Insider 03/06 07:43 ET
- INSMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits Yahoo 03/06 07:41 ET
- A Busy Calendar of March Biotech Events The Street 03/03 08:13 ET
- Interim Data on Insmed's Arikace Yahoo 02/20 16:10 ET
- Interim Data on Insmed's Arikace - Analyst Blog Zacks 02/20 11:10 ET
- Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients noodls 02/19 07:48 ET
- INSMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Yahoo 02/19 07:06 ET
- Insmed provides update from two-year study of ARIKACE Yahoo 02/19 07:04 ET
- Forest Labs buyout may boost other drug stocks Yahoo 02/18 14:20 ET
INSM Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Insmed is up 186.6% over the last year vs S&P 500 Total Return up 24.21%, Jazz Pharmaceuticals up 166.8%, and Novartis up 25.01%.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for INSM
Pro Report PDF for INSM
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download INSM Pro Report PDF
Pro Strategies Featuring INSM
Did Insmed make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: New Jersey
- Incorporation Country: United States
- Incorporation State/Province: Virginia
Insmed, Inc. is a biopharmaceutical company engaged in developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Its lead product candidate is ARIKAYCE.